Cost-effectiveness analysis of a vaccine for Helicobacter pylori in southern Europe
e202403017
Keywords:
Cost-effectiveness, Gastric cancer, Peptic ulcer disease, Helicobacter pylori, VaccineAbstract
BACKGROUND // There is sufficient evidence on the feasibility of a vaccine to prevent Helicobacter pylori infection. Modeling studies in low prevalence environments report a very probable long-term cost-effectiveness. The objective of this study was to quantify its efficiency in a local context.
METHODS // The evolution of a cohort of newborns was simulated through a compartmental model representing a series of clinical situations regarding H. pylori infection and related diseases. The model was run under the assumption of both vaccination in the first year of life and no intervention. The time horizon was set as equivalent to the life expectancy and the perspective of the health system was taken into account.
RESULTS // Vaccination against H. pylori would cost an average of €2,168/person more than no intervention. This would yield an average additional 0.32 quality-adjusted life years gained (QALY), which would entail an incremental cost-effectiveness ratio (ICER) of €7,196/QALY. For a willingness to pay of €24,506/QALY, 99.96% of the simulations were cost-effective at eighty-four years old. This threshold was crossed thirty years after vaccination. The variables that carried the most weight in explaining the variability of the ICER were, in this order, vaccine effectiveness, the incidence of infection in young children, and the price of the vaccine. Vaccination would cease to be cost-effective with a price greater than €3,634/dose or with effective population coverage less than 11%.
CONCLUSIONS // When implemented in an environment with the epidemiological and economic characteristics of Southern Europe, a prophylactic vaccination against H. pylori would be cost-effective in the long run.
Downloads
References
Hooi JKY, Lai WY, Ng WK et al. Global Prevalence of Helicobacter pylori Infec-tion: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153:420-429.
Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646-664.
Pan K, Zhang L, Gerhard M et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut. 2016;65:9-18.
Jones NL, Koletzko S, Goodman K et al. Joint ESPGHAN/NASPGHAN Guide-lines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr. 2017;64:991-1003.
Sutton P, Boag JM. Status of vaccine research and development for Helico-bacter pylori. Vaccine. 2019;37:7295-7299.
Rupnow MFT, Chang AH, Shachter RD et al. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J Infect Dis. 2009;200:1311-1317.
Rupnow MF, Shachter RD, Owens DK et al. A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States. Emerg Infect Dis. 2000;6:228-237.
Rupnow MF, Shachter RD, Owens DK et al. Quantifying the population im-pact of a prophylactic Helicobacter pylori vaccine. Vaccine. 2001;20:879-885.
Rupnow MF, Owens DK, Shachter R et al. Helicobacter pylori vaccine develo-pment and use: a cost-effectiveness analysis using the Institute of Medicine Methodology. Helicobacter. 1999;4:272-280.
Yuan C, Adeloye D, Luk TT et al. The global prevalence of and factors associa-ted with Helicobacter pylori infection in children: a systematic review and meta-analysis. Lancet Child Adolesc Heal. 2022;6:185-194.
Sung JJY, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009;29:938-946.
Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk fac-tors and prevention. Prz Gastroenterol. 2019;14:26-38.
Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175-1186.
Go MF. Review article: natural history and epidemiology of Helicobacter py-lori infection. Aliment Pharmacol Ther. 2002;16 Suppl 1:3-15.
Zeng M, Mao X-H, Li J-X et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2015;386:1457-1464.
Choi IJ, Kim CG, Lee JY et al. Family History of Gastric Cancer and Helicobac-ter pylori Treatment. N Engl J Med. 2020;382:427-436.
Gómez Rodríguez BJ, Rojas Feria M, García Montes MJ et al. Incidence and factors influencing on Helicobacter pylori infection recurrence. Rev Esp En-ferm Dig. 2004;96:620-3; 424-427.
Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Phar-macol Ther. 1995;9 Suppl 2:45-51.
Instituto Nacional de Estadística. Tablas de mortalidad por año, sexo, edad y funciones. Series desde 1991. Disponible en: https://www.ine.es/jaxiT3/Datos.htm?t=27153 [consultado agosto 2023].
Sociedad Española de Oncología Médica. Las cifras del cáncer en España 2021. Disponible en: https://seom.org/images/Cifras_del_cancer_en_Espnaha_2021.pdf [con-sultado agosto 2023].
XLSTAT statistical and data analysis solution [programa de ordenador]. Ver-sión 2022.2.1. New York, USA: Addinsoft; 2022.
Lipscomb J, Weinstein M, Torrance G. Time preference. En: Gold M, Siegel J, Russel L, Weinstein M, editores. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. p. 214-216.
Barkun A, Leontiadis G. Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. Am J Med. 2010;123:358-366.e2.
Willems JS, Sanders CR. Cost-effectiveness and cost-benefit analyses of vaccines. J Infect Dis. 1981;144:486-493.
Diari Oficial de la Generalitat de Catalunya. ORDRE SLT/71/2020, de 2 de juny, per la qual es regulen els supòsits i conceptes facturables i es aproven els preus públics corresponents als serveis que presta l’Institut Català de la Sa-lut. 2020. p. 1-173. Disponible en: https://portaldogc.gencat.cat/utilsEADOP/PDF/8153/1799007.pdf [consul-tado agosto 2023].
Ministerio de Sanidad. Contabilidad analítica del Sistema de Información Sanitaria del Ministerio de Sanidad. 2019. Disponible en: https://www.sanidad.gob.es/estadEstudios/estadisticas/inforRecopilaciones/anaDesarrolloGDR.htm [consultado agosto 2022].
Calabozo Freile B, Miranda Hidalgo MR. Tratamiento erradicador de H. pylori. Limitaciones y sobrecoste para el paciente de Pylera®. Ojo Markov. 2017;60:1-4.
Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27:746-761.
Plummer M, Franceschi S, Vignat J et al. Global burden of gastric cancer at-tributable to Helicobacter pylori. Int J cancer. 2015;136:487-490.
Tobias J, Lebens M, Wai SN et al. Surface expression of Helicobacter pylori HpaA adhesion antigen on Vibrio cholerae, enhanced by co-expressed ente-rotoxigenic Escherichia coli fimbrial antigens. Microb Pathog. 2017;105:177-184.
Downloads
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 José Vicente Arcos-Machancoses, Martín Romero Prada, Elena Crehuá Gaudiza, Cecilia Martínez Costa
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
